Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > February 2014 - Volume 26 - Issue 2 > Severe exacerbation of Crohn’s disease during sunitinib trea...
European Journal of Gastroenterology & Hepatology:
doi: 10.1097/MEG.0b013e328365ac54
Case Reports

Severe exacerbation of Crohn’s disease during sunitinib treatment

Boers-Sonderen, Marye J.a; Mulder, Sasja F.a; Nagtegaal, Iris D.b; Jacobs, Joannes F.M.a,c,d; Wanten, Geert J.e; Hoentjen, Franke; van Herpen, Carla M.a

Collapse Box

Abstract

Sunitinib is a multiple tyrosine kinase inhibitor of the vascular endothelial growth factor and platelet-derived growth factor pathway and inhibits angiogenesis, cell proliferation, and tumor cell invasion, and stimulates apoptosis. Treatment with sunitinib in first-line metastatic renal cell carcinoma improves progression-free survival and overall survival compared with interferon-α. Crohn’s disease is characterized by chronic immune-mediated intestinal inflammation. Although the exact pathogenesis of Crohn’s disease remains unknown, the involvement of angiogenesis is acknowledged. It is unknown whether sunitinib interferes with the natural course of Crohn’s disease. We describe a patient with metastatic renal cell carcinoma and a history of Crohn’s disease who was treated with sunitinib and developed a severe exacerbation of Crohn’s disease. After rechallenge with sunitinib, a second exacerbation occurred. We therefore conclude that angiogenesis inhibitors should be administered with care in patients with a history of Crohn’s disease.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.